InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $16.450 0.28 (1.67%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,589 Release of shares from voluntary escrow 10 Dec 2020 8:20AM $3.550 $16.450 risen by 363.38%
$5,589 FDA New Drug Application for TLX591-CDx Proceeds to Review 9 Dec 2020 8:21AM $3.750 $16.450 risen by 338.67%
$5,589 TGA Priority Review Granted for Prostate Cancer Imaging 7 Dec 2020 10:39AM $3.950 $16.450 risen by 316.46%
$5,589 Overview of ProstACT Phase III Study - Investor supplement 3 Dec 2020 8:25AM $4.000 $16.450 risen by 311.25%
$5,589 ProstACT Phase III Study Clinical Development Update 3 Dec 2020 8:25AM $4.000 $16.450 risen by 311.25%
$5,589 Telix and DuChemBio - South Korea Partnership 3 Dec 2020 8:25AM $4.000 $16.450 risen by 311.25%
$5,589 Investor Briefing on First-in-Human Translation of TLX592 2 Dec 2020 8:57AM $3.720 $16.450 risen by 342.20%
$5,589 Approval for Ph I study of next generation product TLX592 2 Dec 2020 8:55AM $3.720 $16.450 risen by 342.20%
$5,589 FDA Approves 68Ga-PSMA Imaging for Use at UCLA and UCSF 2 Dec 2020 8:49AM $3.720 $16.450 risen by 342.20%
$5,589 Briefing for Investor call - TheraPharm GmbH Acquisition 1 Dec 2020 8:23AM $3.580 $16.450 risen by 359.50%
$5,589 Acquisition of TheraPharm GmbH - Investor Call 30 Nov 2020 9:07AM $3.250 $16.450 risen by 406.15%
$5,589 Proposed issue of Securities - TLX 30 Nov 2020 9:03AM $3.250 $16.450 risen by 406.15%
$5,589 Telix Acquires TheraPharm GmbH 30 Nov 2020 9:03AM $3.250 $16.450 risen by 406.15%
$5,589 Trading Halt 27 Nov 2020 8:26AM $3.250 $16.450 risen by 406.15%
$5,589 Prostate Cancer Therapy FDA Meeting Update 25 Nov 2020 9:21AM $3.150 $16.450 risen by 422.22%
$5,589 NDA for Prostate Cancer Imaging accepted by US FDA 24 Nov 2020 8:22AM $2.840 $16.450 risen by 479.23%
$5,589 TLX receives EUR545k Belgian Research Grant 19 Nov 2020 8:50AM $2.800 $16.450 risen by 487.50%
$5,589 Becoming a substantial holder 9 Nov 2020 4:32PM $2.450 $16.450 risen by 571.43%
$5,589 App 2A quotation for shares issued in strategic transaction 6 Nov 2020 8:23AM $2.240 $16.450 risen by 634.38%
$5,589 Appendix 3Y - change in Director interests - O Buck 3 Nov 2020 9:38AM $2.160 $16.450 risen by 661.57%
$5,589 Cleansing Notice - issue of shares from exercise of options 3 Nov 2020 9:36AM $2.160 $16.450 risen by 661.57%
$5,589 Appendix 2A - issue of shares on exercise of options 3 Nov 2020 9:35AM $2.160 $16.450 risen by 661.57%
$5,589 Investor Briefing - Asia Strategy 3 Nov 2020 8:21AM $2.160 $16.450 risen by 661.57%
$5,589 Investor Call - Strategic Licence and Commercial Partnership 2 Nov 2020 2:21PM $1.675 $16.450 risen by 882.09%
$5,589 Appendix 3B - Proposed Issue of Securities 2 Nov 2020 2:20PM $1.675 $16.450 risen by 882.09%

676 - 700 of 948 results

Page 28 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.